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ABSTRACT  The structure of native and progressively reduced human factor Vlll/von Willebrand 
factor (FVlll/vWF) was examined by electron microscopy and SDS gel electrophoresis and then 
correlated with its biological activities. Highly resolved electron micrographs of well-spaced, 
rotary-shadowed  FVlII/vWF  molecules  showed  their structure to  consist of  a  very  flexible 
filament that contains irregularly spaced small nodules. Filaments ranged from 50 to 1,150 nm 
with a mean length of 478 nm and lacked fixed, large globular domains as seen in fibrinogen 
and IgM. A population of multimeric FVlII/vWF species ranging in molecular weight from 1 to 
5 million daltons and differing in size alternately by one and two subunits was observed on 
SDS-2% polyacrylamide-0.5% agarose gel electrophoresis. With progressive reduction of disul- 
fide  bonds by dithiothreitol (DTT), the electron microscopic size of FVIII/vWF decreased in 
parallel with increased electrophoretic mobility on SDS-agarose gels; between 0.1 and 0.5 mM 
DTT its structure changed from  predominantly fibrillar species to large nodular forms. A 50% 
loss of vWF specific activity and FVIII procoagulant activity occurred at 0.4 mM DTT and 1 mM 
DTT,  respectively, corresponding to  the  reduction  of  4  and  12  disulfide  bonds  of  the  62 
disulfides per 200,000-dalton subunit. We  conclude that reduction of a few critical disulfide 
bonds results in a major structural change by electron microscopy and a concomitant loss of 
~50% of the vWF function. 
Factor VIII/von Willebrand factor (FVIII/vWF) is a circulat- 
ing complex glycoprotein that has two hemostatic functions: 
(a) it corrects the plasma defect in classic hemophilia; and (b) 
it shortens the prolonged bleeding time in patients with von 
Willebrand's disease (1).  Specifically, FVIII procoagulant ac- 
tivity markedly accelerates the generation of activated factor X 
which then increases the rate of prothrombin cleavage to yield 
thrombin (2). The functional status of vWF can be assessed in 
vitro using the antibiotic ristocetin, which promotes the aggre- 
gation of platelets in the presence of normal vWF glycoprotein 
(3). In general, low levels of ristocetin-induced platelet aggre- 
gating activity correlate with the prolongation of the bleeding 
time in most patients with von Willebrand's disease (4).  Puri- 
fied FVIII/vWF exists as a  family of multimers estimated to 
range in molecular weight from 1 to 20 million (5,  6). When 
fully reduced, however, the subunit molecular weight is 200,000 
(7). The FVIII and vWF activities of the FVIII/vWF protein 
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can be separated under a variety of unusual conditions; 99% of 
the  protein  possesses  vWF activity while  <1%  gives  rise  to 
FVIII procoagulant activity (8). Many of the physicochemical 
properties of the vWF glycoprotein are known, but to date the 
FVIII  procoagulant  protein  has  not  been  purified  and  its 
biochemical properties remain undefined (9). 
Studies from several laboratories have shown that the FVIII 
and vWF activities are differentially affected by certain modi- 
fications of the intact FVIII/vWF complex; in some instances, 
these efforts have allowed structure-function correlations to be 
made. For example, FVIII procoagulant activity is extremely 
sensitive to proteolytic degradation, but the ristocetin-induced 
platelet aggregating activity is relatively stable despite cleavage 
of the  FVIII/vWF subunits  to a  much smaller  size (10).  In 
contrast, removal of carbohydrate decreases the platelet aggre- 
gating  activity  of the  FVIII/vWF complex with  no  loss  of 
FVIII procoagulant  activity  (11-13).  Recently  the  effect on 
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has been examined (5,  14-21). There is general agreement that 
reduction with  1 mM dithiothreitol  (DTT) results in a  rapid 
loss of vWF activity and a decrease in the size of FVIII/vWF 
as measured by gel-filtration chromatography, sucrose density 
gradient  ultracentrifugation,  or  agarose  gel  electrophoresis. 
There is no such consensus on the effect of reducing reagents 
on  FVIII procoagulant  activity;  some  suggest  that  disulfide 
bond reduction has little or no effect on this activity (5,  16, 17, 
19, 20), but three laboratories indicate that FVIII procoagulant 
activity is abolished by DTT concentrations ranging from 1 to 
50 mM (14,  15,  18). 
There have been several attempts made to resolve the FVIII/ 
vWF structure by electron microscopy (22-25), but none have 
employed the recently described  improved rotary shadowing 
technique that gives a very reproducible spread of clear, well- 
separated molecules (26, 27). Now, besides presenting the first 
highly  resolved  electron  micrographs  of  individual  native 
FVIII/vWF molecules, we also report the effect of reducing 
reagents on the structure  of FVIII/vWF and  correlate these 
changes with those detected by sodium dodecyl sulfate (SDS) 
gel electrophoresis as well as with the progressive loss of both 
FVIII and vWF activities. 
MATERIALS  AND  METHODS 
Materials 
Intermediate-purity human FVIII/vWF concentrates and platelet-rich plasma 
were obtained from the American Red Cross. Ristocetin was purchased from H. 
Lundbeck and Co.  (Copenhagen, Denmark) and SeaKem agarose from  MCI 
Biomedical (Rockland. MD). [3H]iodoacetic acid and carrier-free Nat25I were the 
products of New England Nuclear (Boston, MA) and Amersham Corp. (Arlington 
Heights, ILL respectively. Biogel Al5m (4% agarose) was purchased from Bio- 
Rad Laboratories (Richmond, CA).  Sepharose-bound lactoperoxidase was ob- 
tained from Millipore Corporation (Bedford, MA). Human IgM was the generous 
gift of Dr. R. Buckley (Duke Medical Center). Fibronectin was purchased from 
LKB Instruments, Inc. (Rockville, MD). 2-mercaptoethanol was purchased from 
Sigma Chemical Co. (St. Louis, MO) within 6 months of this study and stored at 
4°C. All other chemicals were reagent grade or better and used without further 
purification. 
Purification and Characterization  of 
Human FVlII/vWF 
Starting with intermediate-purity concentrates (28), FVIII/vWF was purified 
by polyethylene glycol precipitation and  4%  agarose gel chromatography as 
previously described (29). Highly purified FVIII/vWF was consistently obtained 
and validated by SDS gel electrophoresis  (29). FVIII/vWF protein concentrations 
were estimated from absorbance at 280 nm minus the absorbance at 320 nm 
using an extinction coefficient (E°'~) of 1.23; this method agrees well with values 
given by amino acid analysis or the Lowry protein assay (30). FVIII procoagulant 
activity was measured by the partial thromboplastin time method of Langdell et 
al. (31).  Hemophihc plasma with <1% FVIII procoagulant activity was used as 
substrate and was activated before use by incubation for 6 min at 37°C with 5 
mg of kaolin per ml of plasma. Ristocetin-induced platelet aggregating activity 
was determined as described (32), except that paraformaldehyde-fixed platelets 
were used at a  concentration of about 80,000  per mm  3 and the volumes were 
reduced  to 280 #1 of platelet suspension, 35  #1 of FVIII/vWF,  and 35  #1 of 
ristocetin (15  mg/ml). Paraformaldehyde-fixed platelets were prepared by the 
method of Head et al. (33),  but 0.05% disodium EDTA was used in the Tris- 
glucose buffer and bovine serum albumin was omitted. The radioreceptor assay 
for the binding of native and alkylated FVIII/vWF to paraformaldehyde-fixed 
platelets was that of Kao et al. (32) except that 8 ×  106 platelets per incubation 
were used. For this assay, FVIII/vWF was labeled with Na1251 using insolubilized 
lactoperoxidase (29). 
Alkylation of FVlII/vWF 
In  three  separate  series of alkylations, FVIII/vWF  (1.6-1.9  mg/ml)  was 
reduced with 0.1 mM to 25 mM DTT for 2.5 h at 37°C under nitrogen; control 
incubations of FVIII/vWF without DTT were also included. The buffer was 0.2 
M  ammonium  formate-0.15  M  NaCI-0.01  M  Tris,  pH  7.35,  which had been 
deaerated and perfused with extra-dry nitrogen for 1 h before use. Alkylation of 
reduced  FVIII/vWF  was  performed  for  40  min  in  the  dark at  24°C;  [3H]- 
iodoacetic acid dissolved in 0.5 M Tris-0.15 M NaC1, pH 7.4 was added to give 
a fmal concentration equal to that of DTT. The solution was then exhaustively 
dialyzed against 0.05 M sodium phosphate-0.15 M NaC1, pH 7.35. To quantitate 
alkylation, aliquots of 10-20/d were counted in a liquid scintillation  spectrometer 
(Model 3255,  Packard Instrument Co., Inc.. Downers Grove, IL). Each of the 
alkylated FVIII/vWF samples (1.0-1.4 mg/ml) was then divided and subjected 
to both FVIII and vWF functional assays as well as to electron microscopic and 
SDS gel electrophoretic analyses. 
Electrophoretic  Analysis 
SDS 5% polyacrylamide gel electrophoresis was performed by the method of 
Weber and Osbom (34) or Laemmli (35).  SDS-2%  polyacrylamide-0.5% agarose 
gels were prepared as described by Peacock and Dingman (36),  but were pre- 
electrophorased overnight at  room  temperature  at 40 V  in 0.1%  SDS-0.1  M 
sodium  phosphate,  pH  7.1.  Samples in 0.1%  SDS-6  M  urea-0.01  M  sodium 
phosphate, pH 7.1, were run for 30 min at 2 mA/gel and then at 4.5 mA/gel until 
the dye band reached the bottom. Electrophoresis was also performed in agarose 
according to the method of Fass (6), but using an agarose concentration of 1.5% 
and the Weber and Osborn sample and running buffers (34). A current of 1 mA/ 
gel was used for the first 30 min and then 4 mA/gel for 3.5 h. The agarose gels 
were stained for  15 rain at room temperature in 0.25%  Coomassie Blue, 45% 
methanol,  and  9%  acetic  acid,  and  then  destained  in  14%  acetic  acid-10% 
methanol. Human IgM and its multimers, polymerized according to the method 
of Fass (6), served as high molecular weight standards for nonreduced samples 
and for FVIII/vWF alkylated  after reduction by 0.1 mM DTT. Subunit molecular 
weights of reduced FVIII/vWF were estimated in SDS-agarose gels using the 
following  reduced proteins as standards: thyroglobulin, ferritin, ct2-macroglobuhn, 
myosin, fl-galactosidase, and phosphorylase B. 
Electron Microscopy 
Each  FVIII/vWF  sample,  whether  native or  reduced  and  alkylated, was 
diluted to 30 #g/ml in 0.2 M ammonium formate or 0.2 M ammonium formate- 
0.1  M  NaC1,  pH  7.35,  and mixed with one-half volume of glycerol. A  20-gl 
ahquot of this mixture was sprayed onto freshly cleaved mica, dried in vacuo, and 
rotary shadowed with platinum as previously described (26,  27,  37).  Samples 
were  examined  in  a  Siemens  Elmiskop  101  electron  microscope  at  80  kV 
accelerating voltage with a  50 #m objective aperture. Most micrographs were 
taken at x40,000 magnification and photographically enlarged to x 140,000 final 
magnification. 100 molecules were selected for length measurement if they were 
extended enough so that the contour could be traced with as little ambiguity as 
possible. Contour lengths of native FVIII/vWF and fibronectin were measured 
using a sonic digitizer (Graf-Pen; Scientific Accessories Corp.,  Southport, CT) 
coupled to a PDP-I 1/70 computer (Digital Equipment Corp., Marlboro, MA). 
Lyophilized fibronectin was dissolved in 0.2 M ammonium formate and prepared 
for  microscopy as  described  previously (38).  Many  of the  molecules in  this 
preparation were fragmented, but intact molecules of normal length (~ 140 nm) 
could be found. For comparison, human fibrinogen and IgM samples were also 
prepared for electron microscopy essentially the same way as the FVIII/vWF. 
RESULTS 
Electron Microscopy of Native and 
Reduced FVlII/vWF 
The electron microscopic structure of rotary shadowed native 
FVIII/vWF, presented in Fig.  1, resembles very flexible fila- 
ments with irregularly spaced small nodules and heterogeneous 
lengths.  Other representative  examples of native FVIII/vWF 
from several different preparations are shown in Fig. 2A, which 
further illustrates the variety of their sizes and shapes. At this 
magnification, or higher, a repeating structure for the 200,000- 
dalton FVIII/vWF subunit was not readily discernible and the 
molecules lack fixed, large globular domains as seen in some 
proteins, such as fibrinogen and IgM (Fig. 2 G). The electron 
microscopic structure  of vWF protein,  which  was  separated 
from FVIII procoagulant activity by chromatography in 0.25 
M CaC12 (8), was indistinguishable from that of FVIII/vWF. 
To evaluate the size distribution of FVIII/vWF, the contour 
lengths of 100 native molecules were measured.  They ranged 
from 50 to 1,150 nm with a mean length of 478 nm, as shown 
in  Fig.  3.  The  corresponding molecular weights  were  deter- 
OHMORI  ET  AL.  Electron  Microscopy of Native and Reduced FVIII/vWF  633 FIGurE  1  Electron  micrograph  of rotary shadowed  native human  FVIII/vWF.  x  110,000. 
mined by assuming that the strands were cylinders of 2.5  nm 
diameter and packed with protein of partial specific volume 
0.72 cm3/g (7). This diameter was estimated by comparison to 
the similar strands of fibronectin, a  simpler molecule that is 
well-characterized in terms of mass per unit length (38). When 
specimens of FVIII/vWF and  fibronectin were  prepared si- 
multaneously using both unidirectional and rotary shadowing, 
the average diameter of the FVIII/vWF filament was  ~25% 
larger than that of fibronectin, which had been established as 
2  nm (38,  39).  Using the lengths, the average width and the 
partial specific volume, the molecular weight of the average- 
length  FVIII/vWF molecule  was  estimated  to  be  2  x  106 
daltons with  the standard deviation being 0.9  ×  106 daltons. 
When calculated by this method, the molecules shown in Fig. 
2A  ranged in molecular weight from  1.1  ×  106  to 4.8  x  106 
daltons. It should be noted  that there are some straight seg- 
ments of the vWF strand, of length 35  nm  (Fig.  1),  that are 
remarkably  similar in  appearance  to  fibronectin.  Since  the 
fibronectin  subunit  is  70-80  nm  long,  the  35  nm  straight 
segments  seen  here  may  correspond  to  one-half  of  the 
200,000-dalton vWF subunit. 
The  size  and  shape  of  the  FVIII/vWF  molecules  were 
dramatically altered by progressive reduction and alkylation of 
disulfide bonds. As shown in Fig. 2 B, alkylation after incuba- 
tion of FVIII/vWF with 0.1 mM DTT in dilute neutral buffer 
resulted  in  slightly shorter  fdaments  containing  some  large 
nodules.  Reduction with 0.5  mM DTT  and alkylation trans- 
formed the  structure  of FVIII/vWF into very large nodules 
that were often connected by short t'damentous segments (Fig. 
2 C). There were as many as four nodules per molecule and 
the dimeric structure appeared frequently. The corrected nod- 
ule  diameters  were  12-18  nm  and  were  derived  from  the 
measured diameters by subtracting 4 nm, which represents the 
estimated 2 nm-thick platinum shell around the molecule (26, 
40). At higher concentrations of DTT the structure remained 
nodular, but the filamentous connections were no longer evi- 
dent. Some heterogeneity in nodule size and in the tendency to 
aggregate was seen at 2 mM and 10 mM DTT (Fig. 2D and E, 
respectively); however, the  trend was toward a  single-nodule 
structure of uniform diameter (~10-11  rim) such as shown in 
Fig. 2 F  for FVIII/vWF alkylated after reduction with 25 mM 
DTT. Assuming these nodules are spherical and using a partial 
specific volume of 0.72, the maximum molecular weight of this 
reduced FVIII/vWF form was estimated between 430,000 and 
580,000  daltons. Other experiments in which FVIII/vWF was 
analyzed immediately after reduction at the above DTT con- 
centrations,  but  not  alkylated,  showed  the  same  effects  on 
structure  and  thereby exclude the  possibility that  alkylation 
caused the molecular changes. 
Fig.  2 G  shows  the  rotary  shadowed  electron  microscopic 
structure of some other large plasma proteins for comparison 
with FVIII/vWF: the familiar trinodular structure of fibrino- 
gen  (340,000  daltons) (26) in the upper two panels; the uni- 
formly thin, fdamentous structure of fibronectin (440,000 dal- 
tons) (38)  in the middle panels; and the compact penta- and 
hexanodular structure of IgM (800,000-950,000  daltons) (41) 
at the bottom. 
Electrophoretic Analyses of Native, 
Reduced, and Alkylated FVIII/vWF 
Figure 4a shows the effect of reduction on the structure of 
FVIII/vWF as observed by electrophoresis in SDS-I.5% aga- 
rose.  In  the  absence  of reducing  reagents  FVIII/vWF was 
multimeric with eight bands ranging in molecular weight from 
0.8 x  106 to 7 x  106 daltons (Fig. 4a, lane 1), using crosslinked 
IgM as the standard. The multimeric forms seen in gels 2-6 are 
those of the partially reduced and alkylated FVIII/vWF sam- 
ples for which the electron microscopic structure was shown in 
Fig. 2,  Panels B-F.  At 0.1  mM DTT the predominant bands 
had apparent molecular weights of 0.8 x  106, 1.2 x  106 and 1.6 
x  106 daltons (Fig. 4a, lane 2).  The actual molecular weights 
634  THE  JOURNAL OF  CELL BIOLOGY , VOLUME 95,  1982 FIGURE  2  Selected examples of rotary shadowed native FVIII/vWF  molecules (A)  and of FVIII/vWF  that was alkylated following 
reduction by DTT at 0.1 mM (B), 0.5 mM  (C), 2 mM (D), 10 mM (E), and 25 mM (F). Also, molecules of rotary shadowed human 
fibrinogen (G, top), fibronectin  (G, middle), and IgM (G, bottom). Bar, 100 nm. x  110,000. 
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of these  multimers  are  probably  50-60%  of these  apparent 
values (see  reference 6),  because it is known that crosslinked 
IgM, like other crosslinked proteins, is not an ideal molecular 
weight standard,  especially for comparison with  partially  re- 
duced proteins.  Unfortunately there are no standards  for re- 
duced  proteins  with  such  high  molecular  weights.  Further 
reduction  and  alkylation  sharply  diminished  the  number  of 
higher molecular weight forms. The dominant band resulting 
FIGURE  3  A  histogram  of 
contour  lengths  of  native 
FVIII/vWF.  Molecu[ar  weight 
estimates  used  an  average 
cross-sectional  area of  5  nm  2 
for  the  FVlII/vWF  filaments 
(see text). 
from reduction  at  DTT  concentrations  of 2  mM  or greater 
(Fig. 4a, lanes 4-6)  had the same mobility as fully reduced, 
nonalkylated  FVIII/vWF  (Fig.  4a,  lane  7).  The  apparent 
molecular weight of this band when determined in comparison 
to reduced standards in SDS-agarose gels was 350,000 daltons; 
however, when determined either by Weber-Osborn SDS-poly- 
acrylamide gel electrophoresis or by ultracentrifugation (7), the 
molecular weight was 200,000 daltons and corresponded to the 
monomeric subunit of FVIII/vWF. The faint band above the 
monomer in lanes 4-6 (Fig. 4a) and the major band in gel 3 
(0.5  mM  DTT)  correspond  to  a  dimer  of the  FVIII/vWF 
subunit. 
The  FVIII/vWF samples  that  had  been  progressively  re- 
duced and then alkylated barely penetrated SDS-5% polyacryl- 
amide gels when analyzed by standard  methods (34,  35).  As 
shown  in  Fig.  4b,  when  these  same  samples  were  further 
reduced by heating for 5 min at 90°C with 1 M 2-mercaptoeth- 
anol  in  6  M  urea-0.1%  SDS,  the  multimeric  structure  was 
reduced to a single band which migrated well into the gel,  but 
the mobility of each was inversely proportional to the extent of 
OHMORI  Er  At.  Electron  Microscopy of Native and Reduced FVIII/vWF  635 FIGURE  4  (a)  SDS-1.5%  agarose gel electrophoresis of  FVIII/vWF:  lane  1:  nonreduced; lanes 2-6: alkylated with  [3H]iodoacetic 
acid  (IAA)  after reduction  in  nondenaturing buffer  by DTT  at concentrations of 0.1, 0.5, 2.0,  10, and  25  raM,  respectively; these 
samples were electrophoresed in the absence of reducing agent; lane 7: nonalkylated FVlII/vWF  reduced and electrophoresed in 
the presence of 1.0 M  2-mercaptoethanol; the band marked "2 x  10  s'' (molecular weight) is the monomeric subunit of FVlII/vWF, 
although its apparent molecular weight in agarose is 3.5 x  10  s.  (b)  SDS-5%  polyacrylamide slab gel electrophoresis of FVIII/vWF 
in  the  presence  of  1.0  M  2-mercaptoethanol:  lane  1:  labeled  with  36  iodoacetic  acid  (IAA)  per  200,000-dalton  subunit  after 
reduction in 10 M  urea with 0.5 mM  DTT;  lane 2: labeled with 63 IAA per subunit  following reduction in nondenaturJng buffer 
with 25 mM DTT;  lane 3: labeled with 91 IAA per subunit after reduction in 10 M  urea with 25 mM DTT; lane 4: nonalkylated FVlII/ 
vWF control.  (c)  SDS-2%  polyacrylamide-0.5% agarose gel electrophoresis in the absence of reducing agent: lane  1: FVlII/vWF; 
lane  2: cross-linked  IgM;  lane  3:  FVlII/vWF  labeled with  16  IAA  per subunit  after reduction  in  nondenaturing  buffer;  lane  4: 
labeled with 63  IAA per subunit following reduction of nondenatured FVlII/vWF  with 25 mM DTT.  The major bands comprising 
the multimeric structure of nonreduced FVIII/vWF  shown in C, lane 1 are characterized in Table I. 
prior  alkylation.  Thus  reduced  samples  of FVIII/vWF that 
had 28%, 51%, and 73% of its disulfide bonds alkylated (in Fig. 
4 b, lanes 1, 2, and 3, respectively) appeared increasingly larger 
than fully reduced, nonalkylated FVIII/vWF (Fig. 4b:lane 4), 
which had an apparent molecular weight of 200,000 daltons. 
This effect may be due to decreased binding of SDS as a result 
of the added carboxymethyl groups (42). 
As shown in Fig. 4c, analysis of FVIII/vWF by SDS-2% 
polyacrylamide-0.5%  agarose  gel  electrophoresis  gave  im- 
proved resolution of its multimeric structure compared to that 
observed on SDS-1.5% agarose gels.  As on SDS-agarose gels, 
the  various  multimers  of  partially  reduced  and  alkylated 
FVIII/vWF penetrated  these  gels without further reduction, 
but their mobility decreased with increasing degree of alkyla- 
tion  (Fig.  4c,  lanes  3  and  4).  In  view  of these  effects  of 
alkylation on the mobility of protein-SDS complexes in poly- 
acrylamide gel electrophoretic systems, the two major bands of 
FVIII/vWF alkylated at 25 mM DTT (Fig. 4c, lane 4) must 
be the monomer and dimer of  the 200,000-dalton subunit since: 
(a) their apparent molecular weights differ by a factor of two; 
and (b) the mobility of the lowest band (on either Fig. 4 c, lane 
3 or 4), when corrected for the effect of alkylation, is the same 
as that of  the fully reduced, nonalkylated FVIII/vWF 200,000- 
dalton subunlt. Thus FVIII/vWF reduced with 2 mM DTT or 
more exists primarily in the monomeric and dimeric forms (see 
Fig. 2 D-F and Fig. 4a, lanes 4-6), whereas treatment with 0.5 
mM DTT or less produced only dimers and higher multimers 
of the 200,000-dalton subunit. 
The multimeric structure of  nonreduced FVIII/vWF appears 
in gel I  of Fig. 4c as a series of 12 paired bands with an upper 
apparent  molecular weight of 5.2  x  l0  s.  This progression of 
doublet bands, which was also discernible to a lesser extent on 
TABLE  I 
Multimeric Structure of Nonreduced FVIII/vWF* 
Apparent tool wt X  10  -6  Number of subunits§ 
Band num- 
ber:l:  Total  Difference  Case 1  Case 2 
1  1  ?2  6  5 
0.32 
2  1.5  7-8  6 
0.48 
3  2.0  10  8 
0.28 
4  2.3  11-12  9 
0.48 
5  2.8  14  11 
0.25 
6  3.0  15  12 
0.44 
7  3.4  17  14 
0.28 
8  3.7  18-19  15 
* Determined  by SDS-2% polyacrylamide-0.5%  agarose electrophoresis  using 
cross-linked  IgM multimers as the molecular weight standards. 
:}: Designated  bands  are shown in gel  1 of Fig. 4 c. 
§ Determined  from column  2 using  a subunit apparent molecular weight of 
200,000 daltons for case  1 and 250,000 daltons for case 2. 
SDS-1.5% agarose gels, is characterized in Table I for the major 
multimers. The third column of Table I shows that the spacing 
within  the  doublets  is  about  280,000  daltons,  whereas  the 
spacing between them is 480,000 daltons; these probably rep- 
resent  increments  of one  and  two  subunits.  The  number of 
subunits in each multimer was estimated by dividing its appar- 
ent molecular weight in this  electrophoretic system, given in 
the  second  column  of Table  I,  by  the  apparent  molecular 
weight per  subunit,  which in case  1 was assumed  to be  the 
actual weight of 200,000 daltons and in case 2 was estimated 
from the apparent molecular weight intervals between multi- 
mer bands (third column, Table I) to be 250,000 daltons. 
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FIGURE  5  Effect of partial reduction of FVlll/vWFinnondenaturing 
buffer on alkylation with  [~H]iodoacetic acid  (A)  and consequent 
loss  of vWF  specific activity (0)  as assessed  by ristocetin-induced 
platelet aggregation.  Bars  indicate  +1  SD  for  points  when  six  to 
eight measurements were averaged, vWF activity was assayed in the 
absence of DTT at FVlII/vWF concentrations of 0.4-10.0 #g/ml. The 
concentration  of  the 200,000-dalton  FVIII/vWF  subunit  during  al- 
kylation was 7.4 #M. The incorporation of 10 tool of [3H]acetate per 
mole of FVlII/vWF  subunit corresponded to 4.6 x  10  ° cpm/mg of 
FVlII/vWF  protein. 
required to decrease binding of I~SI-FVIII/vWF by 50% was 
0.7 #g compared with  1.7 ~tg of the reduced protein.  Further 
alkylation of FVIII/vWF at 0.5  mM and 2.0 mM DTT had 
little additional effect on its specific platelet binding capability; 
in each case 50% specific binding was obtained with 2.0 #g of 
the  alkylated  FVIII/vWF. However,  FVIII/vWF specimens 
that were alkylated at DTT concentrations of 10 mM and 25 
mM  were  considerably  less  competitive,  with  50%  specific 
binding occurring at 3.7/zg and 8.7 ktg, respectively. 
There was a very good correlation (r = 0.98) between specific 
platelet  binding and the vWF activity of native or alkylated 
FVIII/vWF  (Fig.  7).  The  initial  rate  of ristocetin-induced 
platelet  agregation was  plotted  as  a  function  of the  percent 
specific  binding  of I'~5I-FVIII/vWF displaced  by  unlabeled 
native or reduced and  alkylated  FVIII/vWF. Native FVIII/ 
vWF and each reduced species had essentially the same vWF 
activity when measured at the different protein concentrations 
required to displace 50% of the I~5I-FVIII/vWF platelet bind- 
ing.  The nonzero y-intercept in  Fig.  7  may reflect  a  greater 
sensitivity of the ristocetin-induced platelet  aggregation mea- 
surement. 
Ristocetin-induced Platelet Aggregating Activity 
of Reduced and Alkylated FVIII/vWF 
This activity, which in Fig. 5 we arbitrarily equate with vWF 
activity, was progressively diminished as disulfide bonds were 
reduced.  FVIII/vWF alkylated after reduction with 0.1  mM 
DTT retained 72% of the vWF specific activity of the nonre- 
duced control, while  FVIII/vWF samples alkylated after re- 
duction with 2 mM and  10 mM DTT had only 38% and  17% 
as much, respectively. The reducing agent 2-mercaptoethanol 
was  10-15 times less  effective than DTT; for example,  treat- 
ment with 5 mM 2-mercaptoethanol as compared to only 0.35 
mM DTT, with or without alkylation, was required to decrease 
the vWF specific activity by 50%. 
The number of disulfide bonds reduced at each DTT con- 
centration  was  estimated  by  alkylation  using  [3H]iodoacetic 
acid,  since  purified  FVIII/vWF, whether  denatured  or not, 
contains no detectable free sulfhydryl groups (43). Fig. 5 shows 
that in the absence of denaturing agents, the maximum number 
of moles of [3H]acetate incorporated per mole of FVIII/vWF 
200,000-dalton  subunit  was  -62  out  of the  total  124  half- 
cystine residues  present  in each  subunit  (7,  43).  However,  a 
50% loss of vWF specific activity occurred when only seven 
molecules of [3H]acetate were incorporated per subunit.  This 
suggests  that  much  of the  vWF activity of the  FVIII/vWF 
molecule depends upon the integrity of a  few labile disulfide 
bonds,  including  some  intersubunit  disulftdes  that  when 
cleaved at 0.5 mM DTT or less release a dimer of the FVIII/ 
vWF subunit. 
Binding of Reduced and Alkylated FV!II/ 
vWF to Platelets 
The effect of reduction of FVIII/vWF on its platelet binding 
in the presence of ristocetin was assessed by competitive dis- 
placement of 125I-FVIII/vWF by serial dilutions of native or 
reduced and alkylated FVIII/vWF. Fig. 6 demonstrates that 
nonreduced FVIII/vWF decreased the specific binding of 1251- 
FVIII/vWF more effectively than FVIII/vWF that had been 
reduced with 0.1 mM DTT; the amount of native FVIII/vWF 
too 
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FIGURE  6  Inhibition of specific binding of 0.1/~g of 12~I-FVIII/vWF 
to platelets by nonreduced  FVIII/vWF  (O)  and  by FVIII/vWF  that 
had  been alkylated after partial reduction with  DTT  at concentra- 
tions of 0,1  mM  (+), 0.5 mM(&),  2.0 mM  (O), 10 mM  (El), and 25 
mM  (A).  Platelets  were  incubated  with  the  1251-FVIII/vWF  and 
unlabeled nonreduced FVIII/vWF or each of the unlabeled alkylated 
forms  of  FVIII/vWF  for  2  h  at 24°C  in 0.5  ml  final  volume. Total 
specific binding corresponded to ~29,000 cpm per incubation. 
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binding  capacity  for  several  concentrations  of  both  native  and 
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FIGURE 8  Loss of  FVIII procoagulant activity when  native FVIII/ 
vWF is reduced with dithiothreitol (0) or 2-mercaptoethanol (D). 
Vertical bars indicate +1 SD for the mean FVIII procoagulant activity 
of six to eight experiments. The  FVlII/vWF concentration during 
reduction was approximately 1.5 mg/ml; thus the concentration of 
the cystinyl residues present was ~0.46 mM. 
FVIII Procoagulant Activity of Reduced 
FVIII/vWF 
The  effect of DTT  and  2-mercaptoethanol on  the  proco- 
agulant  activity of  FVIII/vWF  is  shown  in  Fig.  8.  FVIII 
activity decreased rapidly as the DTT  concentration was in- 
creased above 0.1  mM.  The activity was only 50%  at  1 mM 
DTT, 18% at 10 mM, and 2% of  normal at 50 mM. Interestingly, 
2-mercaptoethanol  inactivated  FVIII  procoagulant  activity 
much  less  effectively,  since  28  mM  was  required  for  50% 
inactivation and 0.5 M  for 98% inactivation. 
DISCUSSION 
This  high-resolution  electron  r0icroscopic  study  of  native 
FVIII/vWF  reveals  its  molecular  structure  to  be  a  highly 
flexible filament which contains irregularly spaced small nod- 
ules (Figs.  1 and 2A). The thin fibrils vary greatly in length, 
ranging from 50 to  1150  nm (Fig. 3),  yet they are strikingly 
uniform  in  width  (2-3  nm).  An  important  feature  of  our 
electron micrographs of native FVIII/vWF is that the filaments 
corresponding to even the largest molecules, which are about 
5  ×  106  daltons,  appear  to  have  only  two  ends.  Although 
perhaps not surprising, the vWF protein separated from the 
FVIII procoagulant activity by gel filtration in 0.25  M calcium 
chloride (8) retained the same electron microscopic structure 
as intact FVIII/vWF. Previous electron microscopic studies of 
shadowed specimens of dried (22) or freeze-etched (23) FVIII/ 
vWF showed large globular particles, 20-50 nm in size, with 
no  internal  structure.  Others  found  that  negatively stained 
FVIII/vWF specimens  appeared  as  globular  particles  with 
marked variation in size and shape (24) or irregularly branched, 
thick fibrils that rarely exceeded 120 nm in overall length (25). 
Such  structures  were  probably aggregates of the  individual 
flbrillar molecules that we demonstrate here. 
As estimated from electron microscopy (Fig. 3),  the range 
and frequency distribution of molecular weights of our nonre- 
duced FVIII/vWI- are in good agreement with  those  deter- 
mined  by  SDS-2%  polyacrylamide-0.5% agarose gel electro- 
phoresis. By either technique, the largest muitimer was ~5  × 
106  daltons  and  the  most  prominent  species was  -2  ×  106 
daltons. This molecular weight distribution is characteristic for 
FVIII/vWF that  is  purified,  as  ours  is,  from  intermediate- 
purity  concentrates.  For  such  preparations,  Weinstein  and 
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Deykin (44) determined a molecular weight range of 1.4-5  x 
106 daltons by SDS-gel electrophoresis. Human  cryoprecipi- 
tate, however, is reported to have FVIII/vWF species of mo- 
lecular weight up to -  10 x  106 daltons by gel filtration or SDS- 
agarose gel electrophoresis (44  46). Importantly this distribu- 
tion of multimer size overlaps significantly with  that  of our 
FVIII/vWF preparations (21, 44). Whether or not the largest 
FVIII/vWF forms actually circulate in vivo remains contro- 
versial. Some investigators have concluded from SDS-gel elec- 
trophoresis of fresh plasma, followed by heterologous antibody 
labeling,  that  FVIII/vWF forms  as  large  as  10-15  million 
daltons are present in plasma (45, 47). Others, however, have 
found by gel filtration that freshly drawn warm plasma does 
not contain the large forms found in cryoprecipitate (18, 48). 
In any case, our preliminary electron micrographs of the ear- 
liest fractions with FVIII/vWF activity from Sephacryl S-1000 
gel filtration of cryoprecipitate reveal FVIII/vWF forms that 
are essentially identical to those shown here, except that some 
are less folded. 
As  FVIII/vWF is  titrated with  the  reducing  agent  DTT, 
there are striking changes in its structure as seen by electron 
microscopy. At  the  lowest  DTT  concentration  tested,  when 
fewer than 0.5% of the disulfide bonds were alkylated, the size 
and number of nodules on the filaments were increased and 
only species smaller than 1.6 million daltons were observed by 
SDS-agarose electrophoresis. Our  findings that  reduction of 
FVIII/vWF with 0.5 mM DTT gives large nodular structures 
of 12-18 nm in diameter, that an average of only five disulfide 
bonds per 200,000-dalton  subunit  are reduced by this  DTT 
concentration, and that the predominant species on SDS-aga- 
rose  gels  is  the  dimer,  indicate  that  only  a  few  interchain 
disulfide bonds are responsible for maintaining the filamentous 
structure of the native FVIII/vWF molecule. With the reduc- 
tion  of 21  disulfide bonds  per  subunit  at  2  mM  DTT,  the 
nodules become considerably more compact (10-11  nm diam- 
eter) and  the predominant band  on  SDS-agarose gels is the 
monomeric subunit. Whereas limited interchain disulfide bond 
reduction accounts for the formation of the globular structures 
at  the  lowest  DTT  levels, reduction  of intrachain  disulfide 
bonds at the higher DTT concentrations may cause the globules 
to become more compact by increasing the potential for hydro- 
phobic interactions. Yet we observed that even when  half of 
the  62  disulfide bonds  per  200,000-dalton  subunit  were  re- 
duced, as occurs at  10 mM DTT, the volume of the resulting 
single nodules can still accommodate up to 500,000 daltons of 
a  compact  globular protein.  It  is  likely,  however,  that  the 
structure of the collapsed vWF filament obtained after reduc- 
tion in nondenaturing buffers is more open and loosely packed 
than that of an intact globular protein. In this case each nodule 
may, as suggested by the agarose gel-electrophoretic analyses, 
correspond to a  single 200,000-dalton subunit. These changes 
in electron microscopic structure are more dramatic than those 
usually seen when a protein is progressively reduced. Reduction 
of fibronectin, for example, results in strands half the length of 
the native dimeric molecule; the structure of these strands is, 
however, identical to that of the unreduced molecules (H. P. 
Erickson, unpublished observations). 
Of the three FVIII/vWF functions tested, the most sensitive 
to  structural  alterations was  its  binding  to  platelets in  the 
presence  of ristocetin.  The  specific binding  of FVIII/vWF 
alkylated at 0.1 mM DTT dropped to 40% of the control level 
when  based on  the  microgram amount  required to  displace 
50% of the 125I-FVIII/vWF  (Fig. 6). On a molar basis, however, 
only 16% binding remained, because at this stage of reduction the mean multimer size of FVIII/vWF as estimated by SDS 
gel electrophoresis was four subunits compared with 10 for that 
of nonreduced  FVIII/vWF.  Platelet  binding  of the  FVIII/ 
vWF dimer, which appears on SDS gels as the major product 
of reduction by 0.5 mM DTT, was ~35% of native FVIII/vWF 
on a weight basis or 7% on a molar basis. The loss of ristocetin- 
induced platelet aggregating activity in reduced FVIII/vWF 
(Fig. 5) was equal to the diminished platelet binding except at 
the lowest DTT concentration tested, for which case the platelet 
aggregating  activity was  disproportionately higher  than  the 
platelet  binding.  Perhaps  the  increased  size  of the  nodular 
regions in the filamentous structure of FVIII/vWF at 0.1 mM 
DTT enhanced the platelet agglutinating effectiveness of those 
FVIII/vWF molecules  that  could  still bind  to  the  platelet 
receptor. Of interest in this respect are the previous reports of 
transitory  enhancement  of FVIII/vWF platelet aggregating 
activity after very limited reduction (16,  19).  In comparison 
with activity losses caused by removal of carbohydrate (11, 12), 
FVIII/vWF alkylated after reduction with 0.1  mM DTT had 
platelet binding similar to asialo-FVIII/vWF and slightly less 
vWF activity per mole. Our losses in ristocetin-induced platelet 
aggregating activity and  platelet binding capacity of FVIII/ 
vWF with progressive reduction are similar in magnitude to 
those recently reported (20). Moreover, the functional losses we 
observed coincided with the very earliest stage in the transfor- 
mation  of  filamentous  FVIII/vWF  multimers  to  globular 
forms. 
In contrast to  the  platelet related activities, FVIII proco- 
agulant activity persisted during these structural changes (Fig. 
8); however, it was not immutable to reduction as others have 
described (5,  16,  17,  19,  20).  A  50%  loss  of FVIII  activity 
occurred at 30 mM  2-mercaptoethanol or at  1 mM  DTT;  in 
either case FVIII/vWF had no  fibrillar structures remaining 
and  was  composed  mainly  of  the  400,000-dalton  dimer. 
Whether this residual activity was stable beyond several hours 
in the absence of the larger vWF multimers was not specifically 
tested.  Because  the  FVIII  procoagulant  moiety  contributes 
<1% of protein content of the FVIII/vWF complex, the meas- 
ured  incorporation of [all]acetate after reduction  of FVIII/ 
vWF (Fig. 5) does not indicate to what extent FVIII itself was 
alkylated. The  final 34%  of the  FVIII procoagulant activity 
was lost between 2 mM and 50 mM DTT when there were no 
further changes in FVIII/vWF structure, as assessed by elec- 
tron  microscopy and  SDS-agarose  gel  electrophoresis.  This 
suggests that alkylation of the FVIII entity may contribute to 
the loss of procoagulant activity. 
At this time we are unable to be exact about the assembly of 
FVIII/vWF into multimers. The remarkable structure of a thin 
filament of mostly uniform diameter indicates that it cannot be 
a  random  polypeptide chain,  but  instead must be  coiled or 
folded into  an  elongated structure  that  propagates along its 
long axis to give the well defined filaments we observe. The 
precise structural model for  FVIII/vWF must  be consistent 
with several additional observations from our work and that of 
others which suggest: (a): The basic unit, or protomer, contains 
two 200,000-dalton subunits joined by disulfide bonds that are 
relatively resistant  to  reduction  in  nondenaturing  solvents. 
Besides data shown here, evidence for such a dimeric protomer 
has been given by Counts et al. (5) and others (44, 49), although 
some have suggested a  tetrameric protomer (45, 47,  50). (b): 
The disulfide bonds that link protomers into a strand are very 
susceptible to reduction in dilute neutral buffers. (c): There is 
a  recurrent  nonuniform  difference  in  molecular  weight  of 
250,000 daltons alternating with 500,000 daltons as the multi- 
mers increase in length (Table I). This is evident as a series of 
doublet bands on SDS-gel electrophoresis (Fig. 4 c, lane 1) and 
has been noted for FVIII/vWF from intermediate-purity con- 
centrates, but not from cryoprecipitate (44). However, a similar 
nonuniformity was recently reported for FVIII/vWF in fresh 
normal plasma and did not appear due to proteolysis (46). (d): 
Because a protomer of 400,000 daltons is released very early in 
the course of reduction, before any 200,000-dalton subunits are 
seen, a model in which each protomer is disulfide-linked with 
a  monomeric  subunit  in  an  alternating  progression  is  not 
possible. Perhaps the vWF multimers are composed ofsubunits 
that differ only in the number and position of their disulfide 
bonds, such as to allow for two different conformational states; 
this  may  then  account  for  the  alternating spacing  observed 
between adjacent bands on  SDS gels of nonreduced FVIII/ 
vWF (Table I). 
Just as with other proteins, we assume that the process of 
FVIII/vWF absorption to a mica surface gives a  distribution 
of molecular shapes similar to that present in solution. To this 
extent  it  is  of interest that  FVIII/vWF may  be  the  largest 
circulating protein, but unlike other plasma macromolecules 
such as IgM, a2-macroglobulin and fibrinogen, it has no prom- 
inent globular domains. It does bear structural similarity to the 
fibrillar protein, fibronectin, which as a uniform length and a 
molecular weight of 440,000  and like FVIII/vWF, is synthe- 
sized by the endothelial cell (38,  39).  Some  have postulated 
that filamentous proteins are well-suited for bridging the dis- 
tances between binding sites located on cell surfaces, Type IV 
collagen and matrix components of basement membranes (38, 
51);  however, the detailed steric arrangements of such multi- 
complexes remain unknown. We speculate that the long fibril- 
lar  FVIII/vWF  multimers  span  the  distances  between  the 
vascular intimal surface and platelets as the latter flow by an 
area  of injury.  In  this  way  the  endothelial cell and  several 
platelets can be brought together to form a platelet mass that 
seals an injured vessel. The FVIII/vWF fibriUar multimers in 
plasma may  collect at  a  site of vascular damage  or simply 
become exposed as a  consequence  of injury to  their cell of 
origin, the endothelial cell. Whether the small forms of FVIII/ 
vWF produced by partial reduction are analogous to the small 
multimers with  decreased  function  in  Type  IIA von  Wille- 
brand's disease (1) is being investigated. 
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